GRCE earnings: real EPS beat/miss history, analyst consensus Buy, P/E -4.26. Updated 2026-07-23.
Grace Therapeutics (GRCE) Research Hub
Grace Therapeutics (GRCE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.22 USD (+3.74%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.26, market cap 0.04B. This hub links to the full technical, earnings and options research available for GRCE.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.22 USD (+3.74%) |
| 52-week range | 1.85 USD – 2.58 USD |
| Trend regime | Range |
| 14-day RSI | 59.2 (Bullish) |
| Trailing P/E | -4.26 |
| Market cap | 0.04B |
| Dividend yield | 0.00% |
Available research for GRCE
Covered Call on GRCE: how it works, illustrative setup around the real 2.22 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GRCE: how it works, illustrative setup around the real 2.22 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GRCE: how it works, illustrative setup around the real 2.22 USD price, max profit/loss, breakeven and when to use it. Educational.
GRCE technical analysis: range, last 2.22 USD, RSI 59.2, 52w range 1.85 USD–2.58 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is GRCE in?
Grace Therapeutics (GRCE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GRCE in an uptrend or downtrend?
As of 2026-09-11, GRCE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GRCE's trailing P/E ratio?
GRCE's trailing P/E is -4.26, with a market cap of 0.04B. See the earnings research page for full valuation detail.